Io Therapeutics, Inc.

Professor Noelle is a co-founder of Io Therapeutics. He is an internationally renowned leader in autoimmune diseases research. He holds joint academic appointments as Professor of Immunology and Microbiology at Dartmouth and Professor of Transplant Science and Immunotherapy at King’s College, London. In addition to his numerous accomplishments in academia, Professor Noelle has also demonstrated entrepreneurial translation of his research into clinical applications. He is a co-founder and Chief Scientific Officer of ImmuRx, Inc., which is developing treatments for cancer and chronic infectious diseases utilizing his discoveries in the CD40 ligand area. Professor Noelle was awarded a $7 M Wellcome Trust Principal Research Fellowship Award (the most prestigious of the Wellcome Trust’s personal awards) to study the role of retinoids in autoimmune disease.

Dr. Corazon (Corsee) Sanders graduated magna cum laude from the University of the Philippines, where she earned B.S. and M.S. degrees in statistics. As a Fulbright Scholar, she earned an M.A. and a Ph.D. in statistics from the Wharton Doctoral Program at the University of Pennsylvania.

Corsee held numerous leadership positions over the course of 23 years at Genentech/Roche, including serving as senior vice president, global head of clinical operations and industry collaboration for six years. She then served as executive vice president of development operations at Juno Therapeutics, and as strategic advisor to the office of the Celgene Chief Medical Officer, following Celgene’s acquisition of Juno. Following acquisition of Celgene by Bristol Myers Squibb (BMS), she served as transition advisor to the BMS clinical development team.

She is a member of the board of directors of four biotechnology companies including three public companies: Ultragenyx, BeOne Medicines Ltd. (formerly Beigene Ltd.), and Legend Biotech Corporation. She is a member of the board of directors of Altrubio, a privately held company. She serves as an advisory committee member for the George Schultz Innovation Fund of the University of Chicago Booth School of Business. She is co-chair of the Board of Advisors and chair of the Science and Technology Advisory Committee for the Fred Hutchinson Cancer Research Center.

Kevin Horgan, M.D. is a board-certified internist and gastroenterologist with extensive experience in therapeutics and diagnostics development. Dr. Horgan received his medical degree from University College, Cork, Ireland and completed training in internal medicine at the Queen Elizabeth Hospital, Birmingham, United Kingdom and at Johns Hopkins University Hospital, Baltimore, MD. Following an immunology research fellowship at the National Cancer Institute in Bethesda, MD, and a gastroenterology fellowship at the University of California at Los Angeles, he served on the UCLA faculty for four years. Dr. Horgan joined Merck in 1997 and led the development of the first neurokinin-1 receptor antagonist, EMEND®, to be approved for the prevention of chemotherapy-induced nausea and vomiting in 2003. From 2006 to 2008, he was Vice President of Clinical Immunology at Centocor Ortho Biotech Inc. In 2008, Dr. Horgan joined General Electric Healthcare as Head of Internal Medicine Research and Development in molecular diagnostics with a focus on oncology and neuroscience, where he designed the development program for GE’s amyloid PET imaging agent flutemetamol.

The company uses the law firm of K&L Gates LLP as its general and intellectual property counsel.